> Detailanzeige

Sousa, J. Eduardo; Costa, Marco A.; Abizaid, Alexandre; Abizaid, Andrea S.; Feres, Fausto; Pinto, Ibraim M. F.; Seixas, Ana C.; Staico, Rodolfo; Mattos, Luiz A.; Sousa, Amanda G. M. R.; Falotico, Robert; Jaeger, Judith; Popma, Jeffrey J.; Serruys, Patrick W.

Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study
  • Beteiligte: Sousa, J. Eduardo; Costa, Marco A.; Abizaid, Alexandre; Abizaid, Andrea S.; Feres, Fausto; Pinto, Ibraim M. F.; Seixas, Ana C.; Staico, Rodolfo; Mattos, Luiz A.; Sousa, Amanda G. M. R.; Falotico, Robert; Jaeger, Judith; Popma, Jeffrey J.; Serruys, Patrick W.
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2001
  • Erschienen in: Circulation, 103 (2001) 2, Seite 192-195
  • Sprache: Englisch
  • DOI: 10.1161/01.cir.103.2.192
  • ISSN: 0009-7322; 1524-4539
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> <jats:italic>Background</jats:italic> —Restenosis remains an important limitation of interventional cardiology. Therefore, we aimed to determine the safety and efficacy of sirolimus (a cell-cycle inhibitor)-coated BX <jats:italic>Velocity</jats:italic> stents. </jats:p> <jats:p> <jats:italic>Methods and Results</jats:italic> —Thirty patients with angina pectoris were electively treated with 2 different formulations of sirolimus-coated stents (slow release [SR], n=15, and fast release [FR], n=15). All stents were successfully delivered, and patients were discharged without clinical complications. Independent core laboratories analyzed angiographic and 3D volumetric intravascular ultrasound data (immediately after procedure and at 4-month follow-up). Eight-month clinical follow-up was obtained for all patients. There was minimal neointimal hyperplasia in both groups (11.0±3.0% in the SR group and 10.4±3.0% in the FR group, <jats:italic>P</jats:italic> =NS) by ultrasound and quantitative coronary angiography (in-stent late loss, 0.09±0.3 mm [SR] and −0.02±0.3 mm [FR]; in-lesion late loss, 0.16±0.3 mm [SR] and −0.1±0.3 mm [FR]). No in-stent or edge restenosis (diameter stenosis ≥50%) was observed. No major clinical events (stent thrombosis, repeat revascularization, myocardial infarction, or death) had occurred by 8 months. </jats:p> <jats:p> <jats:italic>Conclusions</jats:italic> —The implantation of sirolimus-coated BX Velocity stents is feasible and safe and elicits minimal neointimal proliferation. Additional placebo-controlled trials are required to confirm these promising results. </jats:p>
  • Zugangsstatus: Freier Zugang